Inulin-enriched pasta improves intestinal permeability and modifies the circulating levels of zonulin and glucagon-like peptide 2 in healthy young volunteers

被引:73
|
作者
Russo, Francesco [1 ]
Linsalata, Michele [1 ]
Clemente, Caterina [1 ]
Chiloiro, Marisa [2 ]
Orlando, Antonella [1 ]
Marconi, Emanuele [3 ]
Chimienti, Guglielmina [4 ]
Riezzo, Giuseppe [2 ]
机构
[1] Natl Inst Digest Dis IRCCS Saverio de Bellis, Lab Expt Biochem, Bari, Italy
[2] Natl Inst Digest Dis IRCCS Saverio de Bellis, Lab Expt Pathophysiol, Bari, Italy
[3] Univ Molise, DiSTAAM, Campobasso, Italy
[4] Univ Bari, Dept Biochem & Mol Biol, Bari, Italy
关键词
Glucagon-like peptide 2; Intestinal permeability; Inulin; Randomized double-blind crossover study; Zonulin; Human; IRRITABLE-BOWEL-SYNDROME; FATTY LIVER-DISEASE; GUT MICROBIOTA; EPITHELIAL BARRIER; GROWTH-FACTOR; OBESE MICE; OLIGOFRUCTOSE; DIET; PATHOGENESIS; OVERWEIGHT;
D O I
10.1016/j.nutres.2012.09.010
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Apart from the intestinal environment, inulin induces physiological effects, which includes a reduction in glucose and lipid concentrations and modulation of gastrointestinal motility through the release of different peptides. We hypothesized that inulin-enriched pasta may also improve small intestine permeability in relation to zonulin and glucagon-like peptide 2 (GLP-2) levels in healthy young subjects. Twenty healthy, young male volunteers completed a randomized, double-blind crossover study consisting of a 2-week run-in period and two 5-week study periods (11% inulin-enriched or control pasta), with an 8-week washout period in between. The intestinal barrier function was assessed by lactulose-mannitol excretion in urine. Zonulin values and GLP-2 release were evaluated by enzyme-linked immunosorbent assay. In the inulin group, the urinary lactulose recovery was significantly lower than the other 2 groups. There were no significant differences in urinary mannitol levels between groups. Accordingly, the lactulose-mannitol excretion ratio was significantly decreased in the inulin-enriched pasta group compared with the other 2 groups. The inulin-enriched pasta group had significantly lower zonulin serum values and significantly higher GLP-2 basal values when compared with the baseline and control pasta groups. The dietary use of inulin-enriched pasta preserves intestinal mucosal barrier functioning and modulates circulating levels of zonulin and GLP-2, suggesting that prebiotics could be used in the prevention of gastrointestinal diseases and metabolic disorders. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:940 / 946
页数:7
相关论文
共 50 条
  • [21] Glucagon-like peptide-2 (GLP-2) modulates intestinal permeability in the parenterally fed neonatal gut
    Kansagra, K
    Stoll, B
    Lu, XF
    Rognerud, C
    Ou, CN
    Burrin, D
    FASEB JOURNAL, 2003, 17 (04): : A305 - A305
  • [22] Glucagon-like peptide-2 (GLP-2) reduces intestinal epithelial permeability of both the paracellular and transcellular pathway.
    Benjamin, MA
    McKay, DM
    Perdue, MH
    GASTROENTEROLOGY, 1998, 114 (04) : A1129 - A1129
  • [23] Alterations in intestinal morphology, histology and permeability with exogenous glucagon-like peptide 2 and epidermal growth factor treatment promote intestinal adaptation in neonatal intestinal failure
    Lim, David
    Levesque, Crystal
    Wales, Paul
    Vine, Donna
    Borthwick, Faye
    Nation, Patrick
    Wizzard, Pamela
    Josephson, Jessica
    Sigalet, David
    Bigam, David
    Li, Julang
    Turner, Justine
    FASEB JOURNAL, 2014, 28 (01):
  • [24] Glucagon-like peptide-2 improves intestinal immune function and diminishes bacterial translocation in a mouse model of parenteral nutrition
    Lei, Qiucheng
    Bi, Jingcheng
    Chen, Huanwei
    Tian, Feng
    Gao, Xuejin
    Li, Ning
    Wang, Xinying
    NUTRITION RESEARCH, 2018, 49 : 56 - 66
  • [25] Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes
    Preiss, David
    Dawed, Adem
    Welsh, Paul
    Heggie, Alison
    Jones, Angus G.
    Dekker, Jacqueline
    Koivula, Robert
    Hansen, Tue H.
    Stewart, Caitlin
    Holman, Rury R.
    Franks, Paul W.
    Walker, Mark
    Pearson, Ewan R.
    Sattar, Naveed
    DIABETES OBESITY & METABOLISM, 2017, 19 (03): : 356 - 363
  • [26] Glucagon-Like Peptide-2 Reduces Intestinal Permeability But Does Not Modify the Onset of Type 1 Diabetes in the Nonobese Diabetic Mouse
    Hadjiyanni, Irene
    Li, Kunmin Karen
    Drucker, Daniel J.
    ENDOCRINOLOGY, 2009, 150 (02) : 592 - 599
  • [27] Glucagon-Like Peptide-2 Induces Rapid Adaptation and Improves Function of the Remnant Intestine Following Intestinal Resection in Preterm Neonates
    Vegge, Andreas
    Thymann, Thomas
    Stoll, Barbara
    Lund, Pernille
    Qvist, Niels
    Hartmann, Bolette
    Jelsing, Jacob
    Jeppesen, Palle B.
    Holst, Jens J.
    Sangild, Per T.
    GASTROENTEROLOGY, 2011, 140 (05) : S197 - S198
  • [28] Exogenous glucagon-like peptide-2 improves outcomes of intestinal adaptation in a distal-intestinal resection neonatal piglet model of short bowel syndrome
    Suri, Megha
    Turner, Justine M.
    Sigalet, David L.
    Wizzard, Pamela R.
    Nation, Patrick N.
    Ball, Ron O.
    Pencharz, Paul B.
    Brubaker, Patricia L.
    Wales, Paul W.
    PEDIATRIC RESEARCH, 2014, 76 (04) : 370 - 377
  • [29] Exogenous glucagon-like peptide-2 improves outcomes of intestinal adaptation in a distal-intestinal resection neonatal piglet model of short bowel syndrome
    Megha Suri
    Justine M. Turner
    David L. Sigalet
    Pamela R. Wizzard
    Patrick N. Nation
    Ron O. Ball
    Paul B. Pencharz
    Patricia L. Brubaker
    Paul W. Wales
    Pediatric Research, 2014, 76 : 370 - 377
  • [30] Correlation between plasma glucagon-like peptide 2 levels and proliferative makers in small intestinal injury in rats induced by methotrexate administration
    Hirotani, Yoshihiko
    Yamamoto, Kaoru
    Ikeda, Kenjl
    Arakawa, Yukio
    Li, Jun
    Kitamura, Kazuyuki
    Kurokawa, Nobuo
    Tanakae, Kazuhiko
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2006, 29 (11) : 2327 - 2330